On Thursday, STAT published a story claiming that IBM is halting sales of Watson for Drug Discovery — a service that uses the company’s Watson AI to analyze connections between genes, drugs, and diseases on the hunt for useful new medications — citing as its source a person familiar with IBM’s internal decision-making.
“We are focusing our resources within Watson Health to double down on the adjacent field of clinical development where we see an even greater market need for our data and AI capabilities,” an IBM spokesperson told STAT — a sign that eight years after launching Watson Health, IBM still isn’t quite sure how AI should factor into the future of healthcare.
The STAT source cited a “lackluster financial performance” as IBM’s reason for no longer developing and selling Watson for Drug Discovery. That mirrors the “lack of demand” reasoning IBM gave for scaling back the part of Watson Health dedicated to helping hospitals manage certain contracts in June 2018.
To Read Complete Article Click on the above link: https://futurism.com/the-byte/ibm-watson-ai-drug-discovery
Image Courtesy: Futurism.com
Transcription is the process of converting audio or video files into text. Every category of… Read More
With ages, the way of marketing has evolved. Email marketing has been a crucial form… Read More
The industry leader in the Android mobile games market is Unity, with a three-fourth share.… Read More
As social media platforms have become our companions, consumers expect various brands to be present.… Read More
Outsourcing is a practice in business whereby a company or an organization recruits a third… Read More